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Background
The Good Participatory Practice (GPP) Guidelines for bio-
medical HIV prevention trials were published by UNAIDS
and AVAC in November, 2007. AVAC conducted a survey
over two months in early 2009 to gauge biomedical HIV
prevention stakeholder awareness and utilization of the
GPP guidelines, attitudes around community engagement
in biomedical HIV prevention trials, and to identify gaps
in achieving appropriate community engagement.
Methods
The GPP survey was designed to gather baseline awareness
and utilization of the GPP guidelines and was directed at
biomedical HIV prevention trial sponsors and networks,
trial site staff, community members and regulators. The
survey was distributed to stakeholders using list serves,
email, and website postings, and was available in English,
French, Portuguese, and Spanish. Survey Monkey was
used to capture and tabulate data.
Results
Widespread response was gained with 533 individuals
from 68 countries responding to the survey. 10% of
respondents were individuals representing trial sponsors
or network headquarters, 32% were trial site staff, 57%
were community representatives, and 1% of respondents
were members of regulatory bodies. Awareness of the
guidelines was 63% percent, yet only 50% of those aware
of the guidelines had read them. 93% of sponsors said
they expected their sponsored trial sites to work collabo-
ratively with communities. However, only 32% of trial
site-based respondents reported receiving guidelines
about community engagement from their sponsors that
they were required to follow.
Conclusion
While awareness of the GPP guidelines is increasing,
efforts must continue to orient stakeholders to their con-
tent and build support for their adoption by trial spon-
sors. Results from the survey indicate that although there
is a high level of reported interest in community engage-
ment across stakeholders, trial sites need more funds and
support to appropriately implement the minimum ele-
ments of good participatory practice.
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